108 related articles for article (PubMed ID: 1491124)
1. Lack of any estrogenic effect of ipriflavone in postmenopausal women.
Melis GB; Paoletti AM; Cagnacci A; Bufalino L; Spinetti A; Gambacciani M; Fioretti P
J Endocrinol Invest; 1992 Nov; 15(10):755-61. PubMed ID: 1491124
[TBL] [Abstract][Full Text] [Related]
2. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
3. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
Agnusdei D; Gennari C; Bufalino L
Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
[TBL] [Abstract][Full Text] [Related]
4. The effects of estrogen and progestin on endogenous opioid activity in oophorectomized women.
Shoupe D; Montz FJ; Lobo RA
J Clin Endocrinol Metab; 1985 Jan; 60(1):178-83. PubMed ID: 2981084
[TBL] [Abstract][Full Text] [Related]
5. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
[TBL] [Abstract][Full Text] [Related]
6. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
de Aloysio D; Gambacciani M; Altieri P; Ciaponi M; Ventura V; Mura M; Genazzani AR; Bottiglioni F
Gynecol Endocrinol; 1997 Aug; 11(4):289-93. PubMed ID: 9272427
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
[TBL] [Abstract][Full Text] [Related]
8. [Ipriflavone].
Kitatani K; Morii H
Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
[TBL] [Abstract][Full Text] [Related]
9. Evidence that estrogens inhibit LH secretion through opioids in postmenopausal women using naloxone.
Melis GB; Paoletti AM; Gambacciani M; Mais V; Fioretti P
Neuroendocrinology; 1984 Jul; 39(1):60-3. PubMed ID: 6087184
[TBL] [Abstract][Full Text] [Related]
10. Sex steroids modulate prolactin response to naloxone in postmenopausal women.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Cagnacci A; Petacchi FD; Fioretti P
Neuroendocrinology; 1985 Aug; 41(2):138-41. PubMed ID: 2995857
[TBL] [Abstract][Full Text] [Related]
11. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
12. Effects of transdermal 17 beta-estradiol treatment and naloxone infusion on gonadotropin response to gonadotropin-releasing hormone in postmenopausal women.
Cagnacci A; Melis GB; Paoletti AM; Soldani R; Fioretti P
J Clin Endocrinol Metab; 1990 Feb; 70(2):365-70. PubMed ID: 2105330
[TBL] [Abstract][Full Text] [Related]
13. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
14. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women.
Mandel FP; Geola FL; Meldrum DR; Lu JH; Eggena P; Sambhi MP; Hershman JM; Judd HL
J Clin Endocrinol Metab; 1983 Jul; 57(1):133-9. PubMed ID: 6304131
[TBL] [Abstract][Full Text] [Related]
16. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women.
Blum I; Vered Y; Lifshitz A; Harel D; Blum M; Nordenberg Y; Harsat A; Sulkes J; Gabbay U; Graff E
Isr J Med Sci; 1996 Dec; 32(12):1158-62. PubMed ID: 9007144
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium valproate on luteinizing hormone secretion in pre- and postmenopausal women and its modulation by naloxone infusion.
Popovic V; Spremovic-Radjenovic S; Eric-Marinkovic J; Grossman A
J Clin Endocrinol Metab; 1996 Jul; 81(7):2520-4. PubMed ID: 8675571
[TBL] [Abstract][Full Text] [Related]
18. Soy germ isoflavones improve menopausal symptoms but have no effect on blood lipids in early postmenopausal Chinese women: a randomized placebo-controlled trial.
Ye YB; Wang ZL; Zhuo SY; Lu W; Liao HF; Verbruggen M; Fang S; Mai HY; Chen YM; Su YX
Menopause; 2012 Jul; 19(7):791-8. PubMed ID: 22278344
[TBL] [Abstract][Full Text] [Related]
19. Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women.
Sharpless JL; Supko JG; Martin KA; Hall JE
J Clin Endocrinol Metab; 1999 Feb; 84(2):688-94. PubMed ID: 10022439
[TBL] [Abstract][Full Text] [Related]
20. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia.
Cook CB; Nippoldt TB; Kletter GB; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
